Expertise in
1
conditions

Dr. Coty H. Ho

Oncology
Bucher Hematology/Oncology Inc.
1180 N Indian Canyon Dr Ste E218, 
Palm Springs, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
1
conditions
Bucher Hematology/Oncology Inc.
1180 N Indian Canyon Dr Ste E218, 
Palm Springs, CA 

Overview

Coty Ho is an Oncologist practicing medicine in Palm Springs, California.

Dr. Ho is highly rated in 1 condition, according to our data. His clinical expertise encompasses Familial Colorectal Cancer, Breast Cancer, Lung Cancer, and Pleuropulmonary Blastoma.

He is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 9 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in SC

Hospital Affiliations

Conway Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID

Locations

Bucher Hematology/Oncology Inc.
1180 N Indian Canyon Dr Ste E218, Palm Springs, CA 92262

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer
Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer
Enrollment Status: Recruiting
Publish Date: April 02, 2026
Intervention Type: Other
Study Phase: Not Applicable
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice
Enrollment Status: Completed
Publish Date: June 03, 2024
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
A Multicenter, Open-Label, Randomized-Controlled Study of Abemaciclib, a CDK4 and 6 Inhibitor, in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer With Visceral Metastases
Enrollment Status: Terminated
Publish Date: August 24, 2021
Intervention Type: Drug
Study Phase: Phase 4
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
A Single-Arm, Global, Phase 4 Study of Abemaciclib, a CDK 4 & 6 Inhibitor, in Combination With Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) in Participants With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast Cancer With Poor Prognostic Factors
Enrollment Status: Withdrawn
Publish Date: September 06, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 8 Less Clinical Trials

3 Total Publications

A Case Series of Rare Immune-Mediated Adverse Reactions at the New Mexico Veterans Affairs Medical Center.
A Case Series of Rare Immune-Mediated Adverse Reactions at the New Mexico Veterans Affairs Medical Center.
Journal: Federal practitioner : for the health care professionals of the VA, DoD, and PHS
Published: November 29, 2023
Similar Doctors
Expertise in
54
conditions
Expertise in
54
conditions
Referral may be required

Eisenhower Lucy Curci Cancer Center

39000 Bob Hope Dr, 
Rancho Mirage, CA 
 (11.5 miles away)
760-674-3602
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Constantin Dasanu is an Oncologist practicing medicine in Rancho Mirage, California. Dr. Dasanu is highly rated in 54 conditions, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, Melanoma, Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Merkel Cell Carcinoma, and Bone Marrow Aspiration.

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

Eisenhower Health

39000 Bob Hope Dr, 
Rancho Mirage, CA 
 (11.5 miles away)
760-674-3604
Languages Spoken:
English
See accepted insurances

Steven Plaxe is an Oncologist practicing medicine in Rancho Mirage, California. Dr. Plaxe is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Ovarian Cancer, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, and Salpingo-Oophorectomy.

Expertise in
52
conditions
Expertise in
52
conditions
Referral may be required

Eisenhower Health

39000 Bob Hope Dr, 
Rancho Mirage, CA 
 (11.5 miles away)
760-341-3688
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Davood Vafai is an Oncologist practicing medicine in Rancho Mirage, California. Dr. Vafai is highly rated in 52 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Anal Cancer, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Coty H. Ho

How do I make an appointment with Dr. Coty H. Ho?

You can book an appointment with Dr. Coty H. Ho by calling their office at 760-416-4749. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Coty H. Ho a top-rated expert for Familial Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Coty H. Ho is classified as an Advanced expert for Familial Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Coty H. Ho specialize in?

While Dr. Coty H. Ho is a Oncology, they have specific expertise in Familial Colorectal Cancer, Breast Cancer, and Lung Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Coty H. Ho participate in research or clinical trials?

Yes. Dr. Coty H. Ho has published 3 articles and abstracts on conditions like Familial Colorectal Cancer. You can view a list of Dr. Coty H. Ho's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Coty H. Ho accept my insurance?

Dr. Coty H. Ho accepts most major insurance plans, including Medicaid. We recommend calling the office directly at 760-416-4749 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ho's expertise for a condition
ConditionClose
      View All 54 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile